AstraZeneca’s Evusheld, the only COVID-19 preexposure prophylaxis treatment with emergency use authorization, isn’t expected to be as effective against new variants, the FDA said in October. The drug is usually used for those who cannot be vaccinated but want protection against the virus.
About a month after the FDA said Evusheld will wane in efficacy against new mutations, the agency warned that Eli Lilly’s COVID-19 drug bebtelovimab is unlikely to neutralize BQ.1 and BQ.1.1. Bebtelovimab is sold commercially for about $2,100 per vial.
It’s unlikely either drug will be pulled from the market if they both continue to offer some protection.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
